ArticleThe EMBO journal2017
The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.
Article in The EMBO journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Protist oxygen-sensing and the role of prolyl hydroxylase-regulation of E3(SCF) ubiquitin ligases.Biochimica et biophysica acta. General subjects · 2026Review
- Bridging Manual and Computational Approaches: The Pseudophosphatase Scanner for Genome-Wide Fungal Pseudophosphatome Analysis.ACS omega · 2026Article
- Glycoregulation of E3(SCF) ubiquitin ligases in unicellular eukaryotes.Glycobiology · 2025Review
- STYX Interacts with FBXW7 to Promote AML Proliferation via Inhibiting the Ubiquitination of CCNE1.Cell biochemistry and biophysics · 2025Article
- Correlations of the expression of Cx43, SCFWorld journal of gastrointestinal oncology · 2025Article
- Molecular insights and clinical implications for the tumor suppressor role of SCFBiochimica et biophysica acta. Reviews on cancer · 2024Review
- Clinical significance of FBXW7 loss of function in human cancers.Molecular cancer · 2022Review
- Pseudophosphatase STYX is induced by Helicobacter pylori and promotes gastric cancer progression by inhibiting FBXO31 function.Cell death & disease · 2022Article
- Evolutionary genomic relationships and coupling in MK-STYX and STYX pseudophosphatases.Scientific reports · 2022Article
- Pseudophosphatases as Regulators of MAPK Signaling.International journal of molecular sciences · 2021Review
- The Roles of Pseudophosphatases in Disease.International journal of molecular sciences · 2021Review
- Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.Breast cancer research : BCR · 2020Article
- STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.Bioscience reports · 2020Article
- FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation.Cell death and differentiation · 2020Article
- Article
- UBTOR/KIAA1024 regulates neurite outgrowth and neoplasia through mTOR signaling.PLoS genetics · 2018Article
- Physiological functions of FBW7 in cancer and metabolism.Cellular signalling · 2018Review
- Article
- The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.The EMBO journal · 2017Article
- MK-STYX Alters the Morphology of Primary Neurons, and Outgrowths in MK-STYX Overexpressing PC-12 Cells Develop a Neuronal Phenotype.Frontiers in molecular biosciences · 2017Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
Abstract
The F-box protein FBXW7 is the substrate-recruiting subunit of an SCF ubiquitin ligase and a major tumor-suppressor protein that is altered in several human malignancies. Loss of function of FBXW7 results in the stabilization of numerous proteins that orchestrate cell proliferation and survival. Little is known about proteins that directly regulate the function of this protein. In the current work, we have mapped the interactome of the enigmatic pseudophosphatase STYX We reasoned that a catalytically inactive phosphatase might have adopted novel mechanisms of action. The STYX interactome contained several F-box proteins, including FBXW7. We show that STYX binds to the F-box domain of FBXW7 and disables its recruitment into the SCF complex. Therefore, STYX acts as a direct inhibitor of FBXW7, affecting the cellular levels of its substrates. Furthermore, we find that levels of STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis. We propose the STYX-FBXW7 interaction as a promising drug target for future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.